Neurolixis to Present Positive Proof-of-Concept Results on NLX-112 at World Parkinson’s Congress  (WPC).

NLX-112, a first-in-kind, highly selective, serotonin 5-HT1A receptor activator, recently underwent a successful Phase 2A clinical trial for treatment of levodopa-induced dyskinesia in Parkinson's disease. The detailed results from the trial, which met its primary and secondary endpoints, will be presented at the WPC in Barcelona as a poster on Wednesday July 5th 2023 (poster board # LBP38.31) and in an oral presentation on Friday July 7th 2023 (morning Hot Topics session). If you are attending this meeting, come and meet us!

See the full press release.



Follow Neurolixis on: